Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
Xenon Pharmaceuticals (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference on October 7, 2024. The company will present a fireside chat at 11:40 am Eastern Time, with a live webcast available on Xenon's website.
Xenon is dedicated to discovering, developing, and delivering life-changing therapeutics for patients with neurological and psychiatric disorders. Their novel product pipeline focuses on areas of high unmet medical need, including epilepsy and depression. The company's lead product, azetukalner, is a Kv7 channel opener in late-stage clinical development for multiple indications, representing the most advanced, clinically validated potassium channel modulator.
Xenon Pharmaceuticals (Nasdaq:XENE), una compagnia biofarmaceutica focalizzata sulla neuroscienza, ha annunciato la sua partecipazione alla prossima BofA Securities 2024 CNS Therapeutics Virtual Conference che si terrà il 7 ottobre 2024. L'azienda presenterà un incontro informale alle 11:40 ora orientale, con una trasmissione in diretta disponibile sul sito web di Xenon.
Xenon è dedicata alla scoperta, allo sviluppo e alla fornitura di terapie che cambiano la vita per i pazienti con disturbi neurologici e psichiatrici. La loro innovativa pipeline di prodotti si concentra su aree di alta esigenza medica non soddisfatta, inclusi epilessia e depressione. Il prodotto principale dell'azienda, azetukalner, è un apritore di canali Kv7 in fase avanzata di sviluppo clinico per molteplici indicazioni, rappresentando il modulatore di canali di potassio clinicamente convalidato più avanzato.
Xenon Pharmaceuticals (Nasdaq:XENE), una compañía biofarmacéutica centrada en la neurociencia, anunció su participación en la próxima BofA Securities 2024 CNS Therapeutics Virtual Conference que se llevará a cabo el 7 de octubre de 2024. La empresa presentará un chat informal a las 11:40 am hora del Este, con una transmisión en vivo disponible en el sitio web de Xenon.
Xenon está dedicada a descubrir, desarrollar y ofrecer terapias que cambian la vida para pacientes con trastornos neurológicos y psiquiátricos. Su innovadora cartera de productos se centra en áreas de alta necesidad médica no satisfecha, incluidos epilepsia y depresión. El producto principal de la compañía, azetukalner, es un abridor de canales Kv7 en desarrollo clínico avanzado para múltiples indicaciones, representando el modulador de canales de potasio clínicamente validado más avanzado.
제논 제약 (Nasdaq:XENE), 신경과학에 중점을 둔 생물의약품 회사가 2024년 10월 7일 개최되는 BofA 증권 2024 CNS 치료제 가상 컨퍼런스에 참여한다고 발표했습니다. 회사는 동부 표준시 기준 오전 11시 40분에 화상 대화를 진행하며, 제논 웹사이트에서 생중계가 제공될 예정입니다.
제논은 신경 및 정신 장애 환자를 위한 인생을 변화시키는 치료제를 발견, 개발 및 제공하는 데 전념하고 있습니다. 그들의 새로운 제품 파이프라인은 간질 및 우울증을 포함한 높은 충족되지 않은 의료 요구가 있는 분야에 중점을 두고 있습니다. 회사의 주요 제품인 아제투칼너는 여러 적응증에 대해 후기 단계의 임상 개발 중인 Kv7 채널 개방제로, 가장 발전된 임상적으로 검증된 칼륨 채널 조절제를 대표합니다.
Xenon Pharmaceuticals (Nasdaq:XENE), une société biopharmaceutique axée sur les neurosciences, a annoncé sa participation à la prochaine BofA Securities 2024 CNS Therapeutics Virtual Conference le 7 octobre 2024. L'entreprise présentera une discussion informelle à 11h40 heure de l'Est, avec une diffusion en direct disponible sur le site Web de Xenon.
Xenon est dédiée à la découverte, au développement et à la fourniture de thérapeutiques qui changent la vie des patients atteints de troubles neurologiques et psychiatriques. Leur pipeline de produits novateurs se concentre sur des domaines présentant un fort besoin médical non satisfait, y compris l'épilepsie et la dépression. Le produit phare de l'entreprise, azetukalner, est un activateur de canaux Kv7 en phase avancée de développement clinique pour diverses indications, représentant le modulateur de canaux potassiques cliniquement validé le plus avancé.
Xenon Pharmaceuticals (Nasdaq:XENE), ein biopharmazeutisches Unternehmen mit Schwerpunkt auf Neurowissenschaften, gab seine Teilnahme an der bevorstehenden BofA Securities 2024 CNS Therapeutics Virtuelle Konferenz am 7. Oktober 2024 bekannt. Das Unternehmen wird um 11:40 Uhr Eastern Time ein informelles Gespräch führen, das per Live-Webcast auf der Website von Xenon verfügbar sein wird.
Xenon widmet sich der Entdeckung, Entwicklung und Bereitstellung lebensverändernder Therapien für Patienten mit neurologischen und psychiatrischen Störungen. Ihre neuartige Produktpipeline konzentriert sich auf Bereiche mit einem hohen medizinischen Bedarf, einschließlich Epilepsie und Depression. Das Hauptprodukt des Unternehmens, azetukalner, ist ein Kv7-Kanalöffner in der späten klinischen Entwicklungsphase für mehrere Indikationen und stellt den fortschrittlichsten klinisch validierten Kaliumkanalmodulator dar.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference taking place October 7, 2024.
| Fireside Chat Presentation Details: | |
| Date: | Monday, October 7, 2024 |
| Time: | 11:40 am Eastern Time |
| Webcast: | Register here |
A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, our lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
When is Xenon Pharmaceuticals (XENE) presenting at the BofA Securities 2024 CNS Therapeutics Virtual Conference?
What is Xenon Pharmaceuticals' (XENE) main focus in drug development?
What is azetukalner and what is its significance for Xenon Pharmaceuticals (XENE)?
How can investors access Xenon Pharmaceuticals' (XENE) presentation at the BofA Securities conference?
